We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-3.5%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$1.82B
AUM Growth
-$609M
Cap. Flow
-$347M
Cap. Flow %
-19.1%
Top 10 Hldgs %
52.59%
Holding
435
New
56
Increased
93
Reduced
114
Closed
122

Top Buys

Rank Stock Value
1
ALKS icon
Alkermes
ALKS
+$9.22M
2
TBRA
Tobira Therapeutics, Inc. Common Stock
TBRA
+$7.3M
3
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$7.22M
4
UTHR icon
United Therapeutics
UTHR
+$5.06M
5
LUMO
Lumos Pharma, Inc. Common Stock
LUMO
+$4.98M

Top Sells

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$22.6M
2
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$18.2M
3
VTRS icon
Viatris
VTRS
+$18.1M
4
PXD
Pioneer Natural Resource Co.
PXD
+$15M
5
EW icon
Edwards Lifesciences
EW
+$11.6M

Sector Composition

Rank Sector Weight
1 Healthcare 10.47%
2 Technology 0.45%
3 Consumer Staples 0.1%
4 Industrials 0.09%
5 Materials 0.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CYTK icon
326
CALL
Cytokinetics
CYTK
$10.9B
– –
-3,106
Closed -$2.08M
CYTK icon
327
PUT
Cytokinetics
CYTK
$10.9B
– –
-1,176
Closed -$787K
ELDN icon
328
Eledon Pharmaceuticals
ELDN
$262M
– –
-4,039
Closed -$6.77M
EXAS
329
DELISTED
Exact Sciences
EXAS
– –
-289,112
Closed -$5.2M
EXAS
330
PUT
DELISTED
Exact Sciences
EXAS
– –
-4,293
Closed -$7.72M
KYNB
331
Kyntra Bio
KYNB
$28.2M
– –
-944
Closed -$517K
GEVO icon
332
Gevo
GEVO
$358M
– –
-250
Closed -$9.82M
GILD icon
333
Gilead Sciences
GILD
$166B
– –
-45,140
Closed -$4.7M
GMED icon
334
Globus Medical
GMED
$10.9B
– –
-16,700
Closed -$345K
GMED icon
335
PUT
Globus Medical
GMED
$10.9B
– –
-913
Closed -$1.89M
HRTX icon
336
Heron Therapeutics
HRTX
$93.4M
– –
-160,323
Closed -$4.29M
IMUX icon
337
Immunic
IMUX
$180M
– –
-97
Closed -$317K
IMUX icon
338
PUT
Immunic
IMUX
$180M
– –
-3
Closed -$404K
LRMR icon
339
PUT
Larimar Therapeutics
LRMR
$392M
– –
-25
Closed -$946K
LXRX icon
340
PUT
Lexicon Pharmaceuticals
LXRX
$1.03B
– –
-260
Closed -$279K
NVAX icon
341
Novavax
NVAX
$1.22B
– –
-26,352
Closed -$4.06M
NVO
342
PUT
Novo Nordisk
NVO
$227B
– –
-168
Closed -$456K
ORMP icon
343
Oramed Pharmaceuticals
ORMP
$170M
– –
-10,558
Closed -$58K
PBYI icon
344
CALL
Puma Biotechnology
PBYI
$404M
– –
-195
Closed -$1.47M
PBYI icon
345
Puma Biotechnology
PBYI
$404M
– –
-26,704
Closed -$2.01M
PBYI icon
346
PUT
Puma Biotechnology
PBYI
$404M
– –
-288
Closed -$2.17M
PCRX icon
347
Pacira BioSciences
PCRX
$1.05B
– –
-31,100
Closed -$1.76M
PLUR icon
348
PUT
Pluri
PLUR
$18.1M
– –
-4
Closed -$53K
PRGO icon
349
CALL
Perrigo
PRGO
$1.44B
– –
-491
Closed -$7.72M
PTCT icon
350
PTC Therapeutics
PTCT
$6.23B
– –
-23,387
Closed -$688K
12 13
14
15 16

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q4 2015 Portfolio in Review

As of Q4 2015, Sabby Management held 435 positions worth $1.82B, down 25% from $2.43B the previous quarter. Its ten largest holdings account for 53% of the portfolio.

Sabby Management withdrew a net $347M in Q4 2015, closing 122 positions and reducing 114 holdings. Its most notable exit was Biogen, an estimated $22.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 10% of assets, down from 13% a quarter earlier, followed by Technology and Consumer Staples.

Against the trend, Sabby Management opened a new position in Alkermes worth $10.5M.

  • Sabby Management's largest Q4 2015 buy was Alkermes: 131,671 shares worth $10.5M.
  • Sabby Management added most to Tobira Therapeutics, Inc. Common Stock in Q4 2015, an estimated $7.3M increase.
  • Sabby Management's biggest Q4 2015 reduction was Edwards Lifesciences, cutting an estimated $11.6M.
  • Sabby Management fully exited Biogen in Q4 2015, selling an estimated $22.6M.
  • Sabby Management's ten largest holdings make up 53% of its $1.82B portfolio in Q4 2015.
  • Sabby Management opened 56 new positions and closed 122 in Q4 2015.
  • Sabby Management's portfolio value fell 25% quarter-over-quarter to $1.82B.

Based on Sabby Management's 13F filing for Q4 2015, filed 16 Feb 2016.